

## [Imipenem + cilastatin + relebactam](#)

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.

The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

Rejected

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.3. Reserve group antibiotics](#)

ATC codes: [J01DH56](#)

EMLc

Indication

Other specified other antibiotic resistant Enterobacterales ICD11 code: [MG50.CY](#)

INN

Imipenem + cilastatin + relebactam

Medicine type

Chemical agent

Antibiotic groups

[RESERVE](#)

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 500 mg + 500 mg + 250 mg powder for injection

EML status history

Application rejected in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

Read more [about patents](#).

Wikipedia

[Imipenem + cilastatin + relebactam](#)

DrugBank

[Imipenem](#),

[Cilastatin](#),

[Relebactam](#)

Summary of evidence and Expert Committee recommendations

The Committee did not recommend inclusion of imipenem + cilastatin + relebactam (IMR) as a Reserve group antibiotic on the complementary list of the EML and EMLc for the treatment of infections caused by multidrug-resistant organisms. The Committee noted that IMR lacks in vitro activity against the carbapenemase genotypes most commonly associated globally with carbapenem resistance in Enterobacterales and that other antibiotics with similar spectrum of activity (e.g. cefiderocol, ceftazidime + avibactam, meropenem + vaborbactam) are already included as Reserve antibiotics on the Model Lists.